Bifemelane, also known as Celeport and Alnert, is a nootropic that has been used to treat individuals with senile dementia in Japan. Aside from its cognition enhancing properties, it has antidepressant and neuroprotective features by acting via the cholinergic system within the brain. The drug has been useful in treating glaucoma.
Bifemelane has a molecular structure of Bifemelane HCl. Its actual synthetic origin belongs to Butanone. The scientific molecular weight of the chemical stands at 269.38 with a pKa of 9.4. In terms of oral absorption, the drug has an absorption rate of 47.5%. Its distribution volume is said to be at 8 ½ kg with a plasma protein binding of 95%. Meanwhile, its pre-systematic metabolism is at 45% with a renal excretion of 0.023% and a 3.3-hour plasma half-life.
Bifemelane is mainly for individuals who have cognitive brain function and those dealing with impaired memory.
Notable Side Effect
Irreversible or significant adverse effects of the drug have led to complications that include delirium and convulsions. Such adverse reactions are triggered by the production of Bifemelane, which can be tolerated. If the results become too severe, they can be symptomatically treated common side effects noted from using the drug include: nausea, vomiting, diarrhea, anxiety, abdominal pain, insomnia, dry mouth, heartburn, excitability, and skin rashes.
Groups at Risk
Bifemelane should never be given to pregnant or nursing mothers, babies, or in patients dealing with any liver malfunction.
Bifemelane should be administered with caution for the elderly and in patients dealing with advanced-stage hepatic disease. At present, its safety usage in children has yet been established.